TENX - Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) | Benzinga
Once granted, this patent will:
- provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040
- broaden IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF
- expressly provide IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF
- expressly provide IP protection for levosimendan in combination with various cardiovascular drugs for use in PH-HFpEF
- represent the third patent granted to Tenax since March of 2023 protecting the use of levosimendan in the treatment of PH-HFpEF.
CHAPEL HILL, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has allowed its patent application with claims covering the use of TNX-103 (oral levosimendan), TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955) and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients and, titled: "LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)."
This new patent, once granted, will provide significant added IP protection through December 2040. The Notice of Allowance indicates that the USPTO plans to grant Tenax expanded IP rights to the use of oral, subcutaneous, and intravenous (IV) administration of levosimendan, as well as its active metabolites (OR1896 and OR1855) for the treatment of PH-HFpEF, at all therapeutic doses. It also indicates that IP protection will be provided for the use of combinations with various cardiovascular drugs, when used in PH-HFpEF patients.
"We are excited to receive a Notice of Allowance of another U.S. patent that will significantly broaden our existing IP claims, including coverage of expanded dose ranges and the combination of levosimendan and other drugs for use in PH-HFpEF. This provides additional rationale for the future development of various drug-drug combinations with levosimendan," said Chris Giordano, President & Chief Executive Officer of Tenax Therapeutics. "Today's patent news adds to the excitement generated by the recent initiation of investigative sites for our Phase ...